Capital Fund Management S.A. Arrowhead Pharmaceuticals, Inc. Transaction History

Capital Fund Management S.A.

$34.4 Billion
Q1 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$26.2 - $36.08 $352,416 - $485,312	-13,451 Reduced 13.48%	86,370 $2.32 Million
Q2 2023 Aug 14, 2023	SELL	$25.16 - $41.38 $148,293 - $243,893	-5,894 Reduced 5.58%	99,821 $3.56 Million
Q1 2023 May 15, 2023	BUY	$23.68 - $38.51 $669,836 - $1.09 Million	28,287 Added 36.53%	105,715 $2.69 Million
Q4 2022 Feb 13, 2023	BUY	$28.0 - $40.56 $111,888 - $162,077	3,996 Added 5.44%	77,428 $3.14 Million
Q3 2022 Nov 14, 2022	BUY	$29.63 - $48.31 $394,286 - $642,861	13,307 Added 22.13%	73,432 $2.43 Billion

Q2 2022 Aug 12, 2022	BUY	$27.79 - $50.61 $405,205 - $737,944	14,581 Added 32.02%	60,125 $2.12 Million
Q1 2022 May 12, 2022	BUY	$39.62 - $69.97 $1.8 Million - $3.19 Million	45,544 New	45,544 $2.09 Million
Q4 2021 Feb 10, 2022	SELL	$58.09 - $82.51 $1.39 Million - $1.98 Million	-23,970 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$58.38 - $84.96 $1.4 Million - $2.04 Million	23,970 New	23,970 $1.5 Million
Q3 2020 Nov 13, 2020	SELL	$33.21 - $51.27 $969,333 - $1.5 Million	-29,188 Closed	0 $0
Q2 2020 Aug 13, 2020	SELL	$26.12 - $43.27 $3 Million - $4.98 Million	-115,038 Reduced 79.76%	29,188 $1.26 Million
Q4 2019 Feb 13, 2020	SELL	$28.14 - $73.01 $1.3 Million - $3.36 Million	-46,075 Reduced 24.21%	144,226 $9.15 Million
Q3 2019 Nov 13, 2019	SELL	$26.26 - $34.86 $238,283 - $316,319	-9,074 Reduced 4.55%	190,301 $5.36 Million
Q2 2019 Aug 12, 2019	BUY	$17.43 - $28.82 $1.64 Million - $2.71 Million	93,942 Added 89.1%	199,375 $5.28 Million
Q1 2019 May 13, 2019	BUY	$12.05 - $20.18 $1.27 Million - $2.13 Million	105,433 New	105,433 $1.94 Million

Others Institutions Holding ARWR

# of Institutions

296

Shares Held

88.5M

Call Options Held

905K

Put Options Held

387K

View Full List

About ARROWHEAD PHARMACEUTICALS, INC.

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $2.71B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

More about ARWR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital Fund Management S.A., based on Form 13F filings with the SEC.

News

Stay updated on Capital Fund Management S.A. with notifications on news.

Account